Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases-Reference-Cited by-同舟云学术

Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases

Published:2012-12-27 Issue:1 Volume:65 Page:48-58
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Haynes Kevin,Beukelman Timothy,Curtis Jeffrey R.,Newcomb Craig,Herrinton Lisa J.,Graham David J.,Solomon Daniel H.,Griffin Marie R.,Chen Lang,Liu Liyan,Saag Kenneth G.,Lewis James D.,

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference38 articles.

1. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study;Baecklund;BMJ,1998

2. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis;Baecklund;Arthritis Rheum,2006

3. The risk of lymphoma development in autoimmune diseases: a meta-analysis;Zintzaras;Arch Intern Med,2005

4. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials;Bongartz;JAMA,2006

5. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials;Bongartz;Ann Rheum Dis,2009

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Necrosis Alpha (TNF-α) Antagonists Used in Chronic Inflammatory Rheumatic Diseases: Risks and their Minimization Measures;Current Drug Safety;2024-11

2. A state-of-the-art systematic review of cancer in hidradenitis suppurativa;Annals of Medicine;2024-07-24

3. The use of biological and targeted synthetic basic anti-inflammatory drugs in elderly patients with rheumatoid arthritis: for or against;Problems of Geroscience;2024-06-30

4. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis;Expert Opinion on Drug Safety;2024-05-23

5. Demographics and treatment trends in the largest cohort of patients with Down syndrome and hidradenitis suppurativa;International Journal of Dermatology;2024-05-23